# A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

> **NCT06223646** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Novatim Immune Therapeutics (Zhejiang) Co., Ltd.** · enrollment: 29 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** KQ-2003 CAR T-cells

## Key facts

- **NCT ID:** NCT06223646
- **Lead sponsor:** Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-11
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2024-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06223646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06223646, "A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06223646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*